Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Shareholder Meeting (November 2026)
45 slides from Arovella Therapeutics's shareholder meeting presentation, Nov 4, 2026
Slide 1: Chair's Address and CEO Presentation to Annual General Meeting
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release For personal use only 4 November 2026 CHAIR’S ADDRESS AND CEO PRESENTATION TO ANNUAL GENERAL MEETING MELBOURNE, AUSTRALIA 4 November 2026: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invari
Slide 2: About Arovella Therapeutics Ltd
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 About Arovella Therapeutics Ltd For personal use only Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid t
Slide 3: Annual General Meeting
ASX:ALA rsonal use only Annual General Meeting Wednesday, 4 November 2026
Slide 4: Introduction
rsonal use only Introduction Mr David Williams
Slide 5: Arovella's Board of Directors
Arovella’s Board of Directors Mr David Williams Dr Nicole Van Der Weerden CHAIRMAN CHIEF EXECUTIVE OFFICER rsonal use only David is one of Australia's best known investment bankers in Dr van der Weerden is an experienced biopharmaceutical pharmaceuticals, medical devices, and in food and executive w
Slide 6: Agenda
Agenda Annual General Meeting, 4 November 2026 rsonal use only Formal Business Chair Address: David Williams CEO Address: Nicole van der Weerden Interview with Jacqueline Cumming: Clinical Development Interview with Michelle Ferguson: Research & Development ASX:ALA 4
Slide 7: Formal Business
Formal Business RESOLUTIONS RESOLUTION 1: Adoption of Remuneration Report rsonal use only RESOLUTION 2: Election of David Williams as a Director RESOLUTION 3: Election of Mark Diamond as a Director RESOLUTION 4: Election of Michael Thurn as a Director RESOLUTION 5: Approval for Issue of Performance
Slide 8: 2026 Annual Report
2026 Annual Report To receive and consider the Financial Report of the Company and its controlled entities and the related rsonal use only Directors' and Auditors' Reports in respect of the financial year ended 30 June 2026. ASX:ALA 6
Slide 9: Resolution 1: Adoption of Remuneration Report
RESOLUTION 1: Adoption of Remuneration Report To consider and, if thought fit, pass with or without amendment the following resolution as a non- rsonal use only binding ordinary resolution: ‘That the Remuneration Report of the Company and its controlled entities for the year ended 30 June 2026 be ad
Slide 10: Resolution 2: Election of David Williams as a Director
RESOLUTION 2: Election of David Williams as a Director To consider and, if thought fit, pass with or without amendment the following resolution as an rsonal use only ordinary resolution: ‘That David Williams, who was appointed a Director on 28 April 2026, retires in accordance with ASX Listing Rule
Slide 11: Resolution 3: Election of Mark Diamond as a Director
RESOLUTION 3: Election of Mark Diamond as a Director To consider and, if thought fit, pass with or without amendment the following resolution as an rsonal use only ordinary resolution: ‘That Mark Diamond, who was appointed a Director on 28 April 2026, retires in accordance with ASX Listing Rule 14.4
Slide 12: Resolution 4: Election of Michael Thurn as a Director
RESOLUTION 4: Election of Michael Thurn as a Director To consider and, if thought fit, pass with or without amendment the following resolution as an rsonal use only ordinary resolution: ‘That Michael Thurn, who was appointed a Director on 28 April 2026, retires in accordance with ASX Listing Rule 14
Slide 13: Resolution 5: Performance Rights to David Williams under the LTIP
RESOLUTION 5: Approval for Issue of Performance Rights to David Williams under the LTIP To consider and, if thought fit, pass with or without amendment the following resolution as an rsonal use only ordinary resolution: ‘That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Sh
Slide 14: Resolution 6: Amendment to Constitution
RESOLUTION 6: Amendment to Constitution To consider and, if thought fit, pass the following resolution as a special resolution: ‘That the constitution of the Company is amended as follows: rsonal use only (a) insert immediately after 'calculated' where appearing in clause 50(c) 'unless the non-cash
Slide 15: Resolution 7: Renewal of Proportional Takeover Provisions
RESOLUTION 7: Renewal of Proportional Takeover Provisions in the Company’s Constitution rsonal use only To consider and, if thought fit, pass the following resolution as a special resolution: 'That, in accordance with section 648G(4) of the Corporations Act 2001 (Cth), approval is given for the rene
Slide 16: Resolution 8: Renewal of Shareholder Approval for the LTIP
RESOLUTION 8: Renewal of Shareholder Approval for the LTIP To consider and, if thought fit, pass with or without amendment the following resolution as an rsonal use only ordinary resolution: ‘That, for the purposes of Listing Rule 7.2 Exception 13 and for all other purposes, the Arovella Long Term I
Slide 17: Resolution 9: Ratification of Prior Issue of Options
RESOLUTION 9: Ratification of Prior Issue of Options rsonal use only To consider and, if thought fit, pass with or without amendment the following resolution as an ordinary resolution: 'That, for the purpose of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issu
Slide 18: Resolution 10: Approval of Additional 10% Placement Capacity
RESOLUTION 10: Approval of Additional 10% Placement Capacity To consider and, if thought fit, pass with or without amendment the following resolution as a special rsonal use only resolution: 'That, for the purpose of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company
Slide 19: Poll
rsonal use only ASX:ALA Poll
Slide 20: CEO Address
rsonal use only CEO Address Dr Nicole Van Der Weerden 18
Slide 21: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 22: Key achievements for FY26
Key achievements for FY26 Transformation to a clinical-stage company Structurally differentiated next-generation cell therapy rsonal use only ALA-101 into clinic ALA-105 into development Pipeline expansion • FDA IND accepted • Potent proof-of-concept data • Expanding ALA-101 into • GMP drug product
Slide 23: Cell Therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T therapies have demonstrated curative potential in blood cancers rsonal use only Cure Product Approval Year 2025 Revenue CAR-T cells have demonstrated ability 2022 US$1.9 bil3 to cure haematological 2017 US$1.5 bil4 cancers Strong 2021 US$1
Slide 24: CAR-T technology challenges
CAR-T technology challenges ALA’s off-the-shelf Only treats the patient who supplied the T cells solution: Manufacturing & supply rsonal use only chain costs high, failures T cell can occur Each T cell manufacturing batch is T cells can be compromised T cell patient-specific by disease Limited centr
Slide 25: CAR-iNKT cells – a differentiated immune cell
CAR-iNKT cells – a differentiated immune cell Potential to overcome core limitations of CAR-T Multiple ways to attack tumours rsonal use only ALLOGENEIC WITHOUT GENE EDITING Off-the-shelf solution; no gene editing required (preserves cell fitness) MULTIPLE WAYS TO KILL CANCER CELLS Reduces the likel
Slide 26: World-class CAR-iNKT manufacturing platform with FDA IND
World-class CAR-iNKT manufacturing platform with FDA IND Semi-automated process suitable for large-scale and late-phase clinical development rsonal use only Arovella Manufacturing Platform Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells to Vial and fr
Slide 27: ALA-101 (CAR19-iNKT cells)
rsonal use only ALA-101 (CAR19-iNKT cells) A next generation off-the-shelf cell therapy for CD19 expressing cancers 25
Slide 28: ALA-101: an off-the-shelf solution for CD19+ blood cancers
ALA-101: an off-the-shelf solution for CD19+ blood cancers First-in-human study commenced rsonal use only Validated target with potential for FDA IND accepted for indication expansion CD19+ lymphomas and Possibility to expand into autoimmunity if phase ALA-101 (CD19 CAR-iNKT) 1 trial supports B cell
Slide 29: ALA-101-001 Phase 1 Study; Blood Cancer
ALA-101-001 Phase 1 study; Blood Cancer Study population Adults with relapsed/refractory NHL (DLBCL • FL • MZL • MCL) CD19-positive B cell cancers Leukaemia (CLL • HCL) Patient journey rsonal use only 4. On-study follow- 5. Long-term follow- 1. Screening 2. Lymphodepletion 3. ALA-101 infusion Confir
Slide 30: The autoimmune opportunity for ALA-101
The autoimmune opportunity for ALA-101 CD19 cell therapy is emerging as a new approach to treat autoimmune disease rsonal use only ALA-101 clinical trial The problem in blood cancers Serious autoimmune diseases such as lupus, myositis, stiff person syndrome, generalized myasthenia gravis, and system
Slide 31: ALA-105 (CLDN18.2 CAR-iNKT)
rsonal use only ALA-105 (CLDN18.2 CAR- iNKT) A clinically validated target that is expressed in several solid tumour types 29
Slide 32: An off-the-shelf solution for solid tumours
An off-the-shelf solution for solid tumours With ALA’s proprietary cytokine armouring rsonal use only Validated target with high unmet need Novel, proprietary Potential to target a broad range of cancers CLDN18.2-targeting CAR ALA-105 (CLDN18.2 CAR-iNKT) Addresses key CAR-T challenges Efficacy – i
Slide 33: CLDN18.2-targeting CAR-iNKT cells are highly potent
CLDN18.2-targeting CAR-iNKT cells are highly potent Complete tumour clearance in gastric cancer animal study Mouse model of advanced gastric cancer rsonal use only Five out of seven (71%) animals treated with the cells survived ALA-105 (CLDN18.2 CAR-iNKT) and showed no sign of tumours after 60-day
Slide 34: ALA-105 path to IND filing
ALA-105 path to IND filing File IND with the FDA rsonal use only Complete IND-enabling studies ALA-105 (CLDN18.2 CAR-iNKT) Manufacture GMP CLDN18.2 CAR lentivirus H1 CY227 Process Development to manufacture ALA-105 Expected INTERACT and preIND meetings with FDA KOL engagement and clinical trial Prot
Slide 35: Summary: One platform - three value-creation pathways
Summary: One platform - three value-creation pathways rsonal use only Core platform: healthy-donor iNKT cells + modular CAR backbone + scalable manufacturing Blood cancer validation -> autoimmunity expansion -> solid-tumour expansion CD19+ blood CD19+ autoimmune CLDN18.2+ solid cancers disease tumou
Slide 36: Arovella's expanding pipeline
Arovella’s expanding pipeline rsonal use only ALA-101 ALA-105 Pipeline expansion Upcoming • Preliminary safety and efficacy • Engagement with FDA • Manufacturing scale-up to • Identify priority solid tumour target for pipeline expansion data from phase 1 trial Milestones • Regulatory filings to expa
Slide 37: Strong Leadership Team
Strong Leadership Team SENIOR MANAGEMENT TEAM rsonal use only Dr Nicole van der Weerden Dr Robson Dossa Dr Michelle Ferguson Jacqueline Cumming CHIEF EXECUTIVE OFFICER VP MANUFACTURING & QUALITY SENIOR DIRECTOR RESEARCH & SENIOR DIRECTOR CLINICAL DEVELOPMENT DEVELOPMENT Drug development, Cell therap
Slide 38: Financial overview
Financial overview Financial Snapshot ASX CODE ALA ALA Price and Volume - 12 Months1 rsonal use only Market capitalisation1 $61.65 million $0.12 Shares on issue 1,208.8 million 40,000,000 52-week low / high $0.047 / $0.100 $0.09 Cash Balance (30 September 2026) $15.6 million2 30,000,000 Major Shareh
Slide 39: Chair Address
Chair Address Mr David Williams rsonal use only • Technology Blood • Trial in Blood • Hospital and Manufacturing Infrastructure • Technology in Tumours • Animal Data in Tumours • Path to FDA • Manufacturing Arrangements • New Hires: • Director – Regulatory • Director – Preclinical • Development Scie
Slide 40: Interview with Jacqueline Cumming: Clinical Development
rsonal use only Interview with Jacqueline Cumming: Clinical Development 38
Slide 41: Interview with Michelle Ferguson: Research & Development
rsonal use only Interview with Michelle Ferguson: Research & Development 39
Slide 42: Q&A
ASX:ALA rsonal use only Q&A Dr Nicole Van Der Weerden CEO
Slide 43: Other Business
rsonal use only Other Business 41
Slide 44: Thank You
ASX:ALA rsonal use only Thank You Email: [email protected] Mobile: +61 403 468 187 David Williams: [email protected] Mobile: +61 414 383 593 Nicole van der Weerden: [email protected] Mobile: +61 407 039 983
Slide 45: Appendix - references
Appendix - references 1. https://www.businesswire.com/news/home/20250210311887/en/CAR-T-Cell-Therapy-Market-Industry-Trends-and-Global-Forecasts-to-2035-CD19-and-BCMA-Have-Emerged-as-the-Most-Popular- Target-Antigens---ResearchAndMarkets.com 2. Zinzi et al., 2023 Pharmacological Research - 10.1016/j
Arovella Therapeutics — Shareholder Meeting (November 2026) on 6ix